Celsion Corporation – Consensus Indicates Potential 330.1% Upside

Broker Ratings

Celsion Corporation with ticker code (CLSN) have now 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 5 and 3 calculating the average target price we see 4. Now with the previous closing price of 0.93 this is indicating there is a potential upside of 330.1%. The 50 day MA is 0.71 and the 200 day moving average is 0.99. The market capitalisation for the company is $33m. Find out more information at: http://www.celsion.com

Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index